Tegaderm CHG securement dressing for vascular access sites in critically ill adults

Resource impact statement

No significant resource impact is anticipated

The NICE medical technologies guidance on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites (issued in July 2015) has been amended.

In updated cost modelling, Tegaderm CHG is shown to be more cost-saving than was considered when the guidance was first issued.

We do not expect this amendment to the guidance to have a significant impact on resources as the potential savings from implementing the recommendations in England are expected to be less than £1 million per year (or £1,800 per 100,000 population).

This is because we do not expect a significant change in use of the technology as a result of the amendments to the guidance.

The technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.